Cohance Lifesciences Limited (BOM:543064)

Market Cap	200.27B
Revenue (ttm)	12.11B
Net Income (ttm)	1.77B
Shares Out	n/a
EPS (ttm)	6.88
PE Ratio	113.16
Forward PE	39.12
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,247
Average Volume	19,475
Open	529.10
Previous Close	527.70
Day's Range	527.15 - 530.45
52-Week Range	518.00 - 1,328.20
Beta	n/a
RSI	30.22
Earnings Date	Feb 12, 2026

About Cohance Lifesciences

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluores...

• Industry: Pharmaceutical Preparations
• Founded: 1989
• Employees: 1,212
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543064

Financial Performance

In 2024, Cohance Lifesciences's revenue was 11.98 billion, an increase of 13.91% compared to the previous year's 10.51 billion. Earnings were 2.68 billion, a decrease of -10.79%.